| 摘要 |
The invention provides an miR gene product which comprises a a nucleotide sequence that is complementary to nucleotides 3741-3749 of SEQ ID NO:55 and which is miR-15a or miR-16-1 for use in treating a cancer associated with overexpression of a BCL2 gene product in a subject, wherein the use comprises administering an effective amount of the miR gene product. The subject may be a human. The cancer may be chronic lymphocytic leukemia (CLL), lymphoma or lung cancer. If the cancer is lymphoma, the lymphoma may be selected from follicular lymphoma, large cell lymphoma and non-Hodgkin's lymphoma. If the cancer is lung cancer, the lung cancer may be non-small cell lung carcinoma. |
